Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 20...(885 $1501251 Other revenue ...)
| HOME >> BIOLOGY >> TECHNOLOGY |
,885 $1,501,251
Other revenue 30,157 8,624 92,991 15,725
Net revenue 373,890 421,384 1,501,876 1,516,976
Cost of sales 223,967 300,313 917,863 1,059,234
Gross profit 149,923 121,071 584,013 457,742
Gross margin 40.1% 28.7% 38.9% 30.2%
Research and development 25,390 26,593 102,426 83,551
Selling and marketing 13,586 13,762 55,350 52,882
Segment contribution $110,947 $80,716 $426,237 $321,309
Segment margin 29.7% 19.2% 28.4% 21.2%
Generic product sales for the fourth quarter of 2007 decreased $69.0 million to $343.7 million, primarily related to the loss of revenue from oxycodone HCl controlled-release tablets. This was offset by new product launches in 2007 of bupropion hydrochloride extended-release 300mg, fentanyl transdermal patch, and Tilia(TM) Fe.
Generic other revenue increased $21.5 million to $30.2 million, due primarily to the addition of royalties from Sandoz's sales of metoprolol succinate extended-release tablets 50mg and GlaxoSmithKline's sales of Wellbutrin XLP(R) 150mg.
Gross margin for the Generic segment increased from 29 percent in the fourth quarter 2006 to 40 percent in the fourth quarter 2007 due to the increase in other revenue, an improvement in product mix and enhanced operational efficiencies.
For the full year 2007, Generic segment product sales decreased 6 percent or $92.4 million to $1.41 billion compared to $1.50 billion for 2006, due primarily to the loss of revenue from oxycodone HCl controlled-release tablets and lower sales of pravastatin sodium tablets.
Generic other revenue increased $77.3 million to $93.0 million for
2007, due primarily to the addition of royalties from Sandoz's sales of
metoprolo
'/>"/>
| SOURCE Watson Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Watson Receives FDA Approval for Generic Accuneb(R)
4. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |